Reversible inactivation of bovine plasma amine oxidase by cysteamine and related analogs
摘要:
Cysteamine (1) was reported many years ago to reversibly inhibit lentil seedling amine oxidase, through the formation of a complex with thioacetaldehyde, the turnover product of 1. Herein, cysteamine (1) and its analogs 2-(methylamino)ethanethiol (3) and 3-aminopropanethiol (6) were found to be reversible inhibitors of bovine plasma amine oxidase (BPAO), but 2-(methylthio)ethylamine (7) was determined to be a weak irreversible inhibitor of BPAO. Based on our results, indicating the necessity of a sulfhydryl-amine for reversible inactivation of BPAO, the failure of inhibited BPAO to recover activity after gel filtration, the first-order kinetics of activity recovery upon dialysis, and 2,4,6-trihydroxyphenylalanine quinine (TPQ) cofactor transformation which indicated from the results of phenylhydrazine titration and substrate protection, we propose a mechanism for the reversible inactivation of BPAO by 1 involving the formation of a cofactor adduct, thiazolidine, between BPAO and 1. (C) 2010 Elsevier Inc. All rights reserved.
A strategy combining quantitative reactions and reversible-covalent chemistry for sequential synthesis of sequence-controlled polymers with different sequences
作者:Chao-Ran Xu、Ze Zhang、Cai-Yuan Pan、Chun-Yan Hong
DOI:10.1016/j.polymer.2019.04.017
日期:2019.5
Diels-Alder reaction, AB-, AB'C- and AB'CD-sequenced molecules polymerize into sequence-controlled polymers with corresponding sequences at 120 °C. Through this strategy, the synthesis of molecular modules does not require separation and purification, and sequence-controlled polymers with specific sequence can be synthesized in a one-pot process via adding different monomers and adjusting reaction condition
[EN] NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS<br/>[FR] NOUVEAUX DÉRIVÉS D'ARYLALCÈNE ET UTILISATION DE CEUX-CI EN TANT QUE MODULATEURS SÉLECTIFS DE RÉCEPTEUR D'OESTROGÈNE
申请人:CENTAURUS BIOPHARMA CO LTD
公开号:WO2013097773A1
公开(公告)日:2013-07-04
The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions.
Conversion of Cysteine into Dehydroalanine Enables Access to Synthetic Histones Bearing Diverse Post-Translational Modifications
作者:Justin M. Chalker、Lukas Lercher、Nathan R. Rose、Christopher J. Schofield、Benjamin G. Davis
DOI:10.1002/anie.201106432
日期:2012.2.20
Six for the price of one: From a single precursor, dehydroalanine, six distinct post‐translational modifications can be site‐selectively installed on histone proteins (see figure), including the first site‐selective phosphorylation and glycosylation of histones. Direct observation of histone deacetylase activity on a full‐length modified histone as well as its interactions with both chromatin reader
Chemical derivatives and their application as antitelomerase agents
申请人:——
公开号:US20030013711A1
公开(公告)日:2003-01-16
The present invention relates to cancer therapies using novel anticancer agents with a specific mechanism of action. The invention also relates to novel chemical compounds and their therapeutic application in man.
NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS
申请人:Centaurus BioPharma Co., Ltd.
公开号:US20150018341A1
公开(公告)日:2015-01-15
The invention provides novel ethylene derivatives represented by Formula I, which may be used as selective estrogen receptor modulators (SERMs) and useful in the prophylaxis and/or treatment of estrogen-dependent conditions or conditions.